Iryna Kryachok

552 total citations
23 papers, 197 citations indexed

About

Iryna Kryachok is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Iryna Kryachok has authored 23 papers receiving a total of 197 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 15 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Iryna Kryachok's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Immunodeficiency and Autoimmune Disorders (6 papers). Iryna Kryachok is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Immunodeficiency and Autoimmune Disorders (6 papers). Iryna Kryachok collaborates with scholars based in Ukraine, Poland and United States. Iryna Kryachok's co-authors include Chumak Aa, Sebastian Grosicki, Iryna Dyagil, M Gorczyca, Yaroslav Kulyaba, Steen Lisby, D. Bаzyка, Ira Gupta, Astrid McKeown and Govind Babu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Iryna Kryachok

21 papers receiving 191 citations

Peers

Iryna Kryachok

GENET

PFM

IMMUN

ONCOL

HEMAT

Jeffrey P. Sharman United States

Jodi Carey United States

Austin I. Kim United States

Mitul Gandhi United States

Fabrizio Luciano Italy

Mia Thorsélius Sweden

Caterina Ilari Italy

Rose Mantel United States

Maneesh Tandon United Kingdom

Josie Montegaard United States

Jeffrey P. Sharman United States

Iryna Kryachok

103 ×0.8

GENET

94 ×0.8

PFM

38 ×0.5

IMMUN

49 ×0.8

ONCOL

43 ×1.2

HEMAT

Citations per year, relative to Iryna Kryachok Iryna Kryachok (= 1×) peers Jeffrey P. Sharman

Countries citing papers authored by Iryna Kryachok

Since Specialization

Citations

This map shows the geographic impact of Iryna Kryachok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iryna Kryachok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iryna Kryachok more than expected).

Fields of papers citing papers by Iryna Kryachok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iryna Kryachok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iryna Kryachok. The network helps show where Iryna Kryachok may publish in the future.

Co-authorship network of co-authors of Iryna Kryachok

This figure shows the co-authorship network connecting the top 25 collaborators of Iryna Kryachok. A scholar is included among the top collaborators of Iryna Kryachok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iryna Kryachok. Iryna Kryachok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kryachok, Iryna, et al.. (2024). INFLUENCE OF COVID-19 AND VACCINATION AGAINST SARS-COV-2 ON THE COURSE OF ONCOHEMATOLOGICAL DISEASES. PART I. GENETIC CHARACTERISTICS OF SARS-COV-2 VARIANTS UPON THE THREE WAVES OF THE PANDEMIC IN UKRAINE. 26(3). 216–221.

Dreyling, Martin, Jiřı́ Mayer, David Belada, et al.. (2024). High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1626–1626. 2 indexed citations

Kryachok, Iryna, et al.. (2023). Assessment of the Nature of Dyslipoproteinemias and Correlations of Indicators of General Reactivity and Lipid Metabolism in Patients with Chronic Nonspecific Inflammation of the Reproductive System. 11(2). 77–94.

Kryachok, Iryna, et al.. (2022). Assessment of the State of Platelet Haemostasis and Adhesive - Aggregation Properties of Platelets as a Factor of Increasing the Tendency to Thrombosis in Chronic Inflammation. 10(2). 22–36. 1 indexed citations

Aa, Chumak, et al.. (2021). The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Leukemia Research. 110. 106686–106686. 1 indexed citations

Kuruvilla, John, Radhakrishnan Ramchandren, Armando Santoro, et al.. (2020). KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).. Journal of Clinical Oncology. 38(15_suppl). 8005–8005. 23 indexed citations

Kryachok, Iryna, et al.. (2020). Профілактика та лікування венозних тромбоемболій у хворих з онкопатологією: проєкт клінічних рекомендацій. 27(3). 75–88. 1 indexed citations

Dimopoulos, Meletios Α., Sosana Delimpasi, Maryana Simonova, et al.. (2020). Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. Journal of Clinical Oncology. 38(15_suppl). 8501–8501. 22 indexed citations

Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL: The Randomised, Controlled, Phase 3 ASCEND Trial. SSRN Electronic Journal. 2 indexed citations

10.

Saenko, Vladimir, et al.. (2017). Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leukemia Research. 58. 1–8. 10 indexed citations

11.

Kryachok, Iryna, et al.. (2016). The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma. Annals of Oncology. 27. vi318–vi318. 1 indexed citations

12.

Österborg, Anders, Andrey Zaritskey, Sebastian Grosicki, et al.. (2016). Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57(9). 2037–2046. 20 indexed citations

13.

Robak, Tadeusz, Krzysztof Warzocha, Govind Babu, et al.. (2016). Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leukemia & lymphoma. 58(5). 1084–1093. 39 indexed citations

14.

Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100. 3 indexed citations

15.

Österborg, Anders, Andrey Zaritskey, Per‐Ola Andersson, et al.. (2014). Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242. Blood. 124(21). 4684–4684. 7 indexed citations

16.

Aa, Chumak, et al.. (2012). CD38 gene polymorphism and risk of chronic lymphocytic leukemia. Leukemia Research. 36(10). 1237–1240. 5 indexed citations

17.

Kryachok, Iryna, et al.. (2011). IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group. Medical Oncology. 29(2). 1093–1101. 7 indexed citations

18.

Aa, Chumak, et al.. (2007). Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident—With focus on immunoglobulin heavy chain gene analysis. Leukemia Research. 32(4). 535–545. 26 indexed citations

19.

Kryachok, Iryna, et al.. (2007). IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.. PubMed. 29(3). 226–30. 6 indexed citations

20.

Kryachok, Iryna, et al.. (2005). Significance of VH genes mutation status for prognosis of CLL patients.. PubMed. 27(4). 325–9. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact